ÌÇÐÄvlogÊÓƵ

 Published: 22 Apr 2020 | Last Updated: 24 Apr 2020 15:33:45

A new MRC grant entitled Treatment of osteoarthritis by inhibition of aggrecanases using targeted delivery of engineered TIMP-3 has been awarded.   This Medical Research Council-funded project is a collaboration between Prof. Andrew Pitsillides (RVC),  (University of East Anglia) and is led by , Brighton and Sussex Medical School.

The project seeks to harness the chondroprotective properties of a natural inhibitor of aggrecanases, named TIMP3, to protect against osteoarthritis. It will employ a novel method of delivering a genetically-modified form of TIMP3, which will have greater specificity capable of targeting its activity only to sites of disease, thus eliminating possible side-effects and increasing its therapeutic efficacy.

High resolution, surface rendered X-ray computerised tomography image of a mouse knee joint
High resolution, surface rendered X-ray computerised tomography image of a mouse knee joint


You may also be interested in:

Top of page